Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 501–600 of 874
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Salah, A. N., Hashem, A. H., Zaki, M. B., Abulsoud, A. I., Atta, A. M., Elkalla, W. S., Moustafa, H. A. M., El‐Dakroury, W. A., El-Tokhy, F. S., ElBoghdady, J. A., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70163 · Cited by 9
Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
Zhang, Y., Chen, J., Wang, X., Wang, H., Chen, X., Hong, J., & Fang, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1624386 · Cited by 10
“Several studies have reported that patients homozygous for the UGT1A1 28 allele experience a higher incidence of severe neutropenia compared to non-carriers (10, 13).”
CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions
Fu, L., Li, Z., Ren, Y., Yu, H., Liu, B., & Qiu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115449 · Cited by 10
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors
LaRose, M., Connolly, R. M., O'Sullivan, C. C., Velcheti, V., Vilimas, R. J., Gano, K., Bates, S. E., Pommier, Y. G., & Thomas, A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad023 · Cited by 9
Ibrahim, R., Khoury, R., Ibrahim, T., Cesne, A. L., & Assi, T. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104265 · Cited by 10
Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions
Jiang, L., Pan, X., & Lang, Z. (2024) · Cancer Reports · doi:10.1002/cnr2.70059 · Cited by 9
A Review of Current and Future Antibody Drug Conjugates in Breast Cancer
Randall, M. E., Akers, R., & Rao, R. D. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01276-3 · Cited by 12
“The median PFS was 5.5 months and OS 13 months [27].”
InfluentialMultifunctional delivery strategies and nanoplatforms of SN-38 in cancer therapeutics
Lozano-García, M., Dikici, E., Bilbao, D., Mohan, P., Deo, S. K., & Daunert, S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113937 · Cited by 12
Qi, X., Li, Y., Liu, W., Wang, Y., Chen, Z., & Lizhu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921385 · Cited by 9
Current therapeutics and treatment options in TNBC
Mir, M. A., Aisha, S., & Mehraj, U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00007-8 · Cited by 11
Antibody-Drug Conjugates Used in Breast Cancers
Abbas, A., Ibrahim, M. F., & Saifo, M. (2021) · Journal of Oncology · doi:10.1155/2021/9927433 · Cited by 9
“(3) Development status [63]: phase I/II.”
Ojo, V. T., Bianchi, N. A., Yi, M. Z., Chung, S. H., Gray, M. E., Rahman, M. A., Elder, K. K., Zhang, T., Brooks, T. A., & Tumey, L. N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02681 · Cited by 8
ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer
Zhang, H., Gao, A., Liu, Q., Zhang, F., Wang, S., Chen, X., Shi, W., Zhang, Y., Liu, Q., Zheng, Y., et al. (2023) · Journal of Cell Science · doi:10.1242/jcs.260964 · Cited by 9
Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?
Santis, P. D., Sanna, V., Perrone, M., Guarini, C., Santoro, A. N., Laface, C., Carrozzo, D., Oliva, G. R., Fancellu, A., & Fedele, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237325 · Cited by 8
Udvorková, N., Fekiačová, A., Majtánová, K., Mego, M., & Kučerová, L. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00200.2024 · Cited by 8
Antibody-drug conjugates in solid tumors: a new frontier
Jaime‐Casas, S., Barragán-Carrillo, R., & Tripathi, A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001064 · Cited by 11
Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis
Xing, M., Li, Z., Cui, Y., He, M., Xing, Y., Yang, L., Liu, Z., Luo, L., Wang, H., & Guo, R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01192-w · Cited by 10
“This drug can deliver high concentrations of SN-38 to tumors, filling a gap in the treatment of (TNBC [19].”
BackgroundDeveloping combination therapies with biologics in triple-negative breast cancer
Gaudio, G., Martino, E., Pellizzari, G., Cavallone, M., Castellano, G., Omar, A. A., Katselashvili, L., Trapani, D., & Curigliano, G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2408756 · Cited by 9
“Sacituzumab govitecan (SG) received FDA accelerated approval following results from the phase I/II IMMU-132-01 trial [119], later confirmed by the phase III ASCENT trial where SG monotherapy in patients with previously treated mTNBC resulted in a significant improvement in ORR, PFS and OS compared…”
Belloni, S., Tiberio, P., Sanctis, R. D., Magon, A., Santoro, A., Zambelli, A., Caruso, R., & Arrigoni, C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104527 · Cited by 12
Antibody-drug conjugates: an evolving approach for melanoma treatment
Anderson, T. S., McCormick, A. L., La-Beck, N. M., Saha, D., & Lowe, D. B. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000702 · Cited by 10
Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report
Papageorgiou, G., Symeonidis, D. G., Tsakatikas, S. A., Liatsos, A. N., Douglas, K. A. A., Douglas, V. P., Moschos, M. M., & Kosmas, C. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001117 · Cited by 8
Sacituzumab Govitecan-hziy in Breast Cancer
Kwapisz, D. M. (2022) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000919 · Cited by 9
Matusz‐Fisher, A., & Tan, A. R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1892 · Cited by 8
Pre-clinical models of small cell lung cancer and the validation of therapeutic targets
Sui, J. S. Y., Martin, P., & Gray, S. G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1732353 · Cited by 8
“It has recently achieved FDA breakthrough therapy status for the treatment of metastatic triple-negative breast cancer (mTNBC) [150,151].”
BackgroundChung, W., Yang, C., Chen, H., Su, C.-Y., Su, H.-W., & Ou, H. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.04.028 · Cited by 8
Chen, J., Feng, L., Sheng, Q., & Li, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/8720679 · Cited by 8
RetractedMcMahon, J. T., Faraj, R. R., & Adamson, D. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1836154 · Cited by 8
Sacituzumab Govitecan in Metastatic Breast Cancer
Ganguly, S., & Gogia, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108478 · Cited by 8
Self-citationKhalaji, A., Hadad, S., Sarmadian, A. J., Ojaghlou, F., Janagard, E. M., & Baradaran, B. (2024) · Current Molecular Medicine · doi:10.2174/0115665240287767240115062343 · Cited by 8
Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy
Lai, J., Deng, S., Cao, J., Ren, Y., Xu, Z., Qi, X., Xu, M., & Liao, N. (2024) · Discover Oncology · doi:10.1007/s12672-024-01261-0 · Cited by 7
“Trop2 is overexpressed in more than 85% of TNBC [11, 12].”
BackgroundNovel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth
Deng, J., Geng, Z., Luan, L., Jiang, D., Lü, J., Zhang, H.-Z., Chen, B.-G., Liu, X., & Xing, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101255 · Cited by 8
García-Sáenz, J. Á., Rodríguez-Lescure, Á., Jurado, J. C., Albanell, J., Alba, E., & Llombart‐Cussac, A. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01125-1 · Cited by 11
“The efficacy of sacituzumab govitecan in metastatic TNBC was assessed in a phase I/II and in a phase III clinical trial [36, 55, 56].”
Navigating liver toxicity in the age of novel oncological agents
Riveiro‐Barciela, M., & Martin, E. D. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101473 · Cited by 9
“65 In an early phase I study, aminotransferase elevations of any grade were reported in 24% of patients for AST and 15% for ALT, while grade 3 elevations were observed in 2.2% of patients for both enzymes.”
InfluentialWang, S., Shen, Y.-C., Pan, M., Ou‐Yang, F., Liao, T.-Y., Liu, L., Rau, K.-M., Lu, L., Huang, C., Dai, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217912 · Cited by 9
Sledge, G. W., Xiu, J., Solzak, J. P., Ribeiro, J. R., Mahtani, R. L., Lustberg, M. B., Oberley, M. J., Radovich, M., & Spetzler, D. B. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02094-7 · Cited by 8
“Though initially being limited to either classic HER2+ MBC (T-DXd) or TNBC (SG), the presence of their cell surface targets outside of these initial subsets led to their expanded use following demonstration of therapeutic efficacy in several pivotal trials trials [2, 3, 5–13].”
Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer
Pulukuri, A. J., Dhull, A., Dar, A. I., Rani, A., Sharma, R. B., Berkman, C. E., & Sharma, A. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00917 · Cited by 10
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
“82,83,90 In contrast, TACSTD2 is highly expressed in the basal-like triple-negative subtype of breast cancer 37 and is similarly associated with a basal-like state in the pancreas cancer (Figure 6A), suggesting its possible role as a basal-like antigen irrespective of primary tumor site.”
Dong, Y., Zhi, Y., Li, X. N., Ma, M., Ye, M., Huang, S., Tang, J. T., Zhong, W., Lei, X., & Mao, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1694436 · Cited by 10
“Existing clinical trial data suggest that the hepatotoxicity of SG is relatively mild, with liver-related AEs primarily consisting of grade 1 – 2 elevations in liver function tests (Bardia et al., 2019; Rugo et al., 2022; Rugo et al., 2023; Bardia et al., 2021; Xu B. et al., 2023).”
Goedhart, T., & Guchelaar, H. (2025) · Clinical and Translational Science · doi:10.1111/cts.70462 · Cited by 7
Roche, S., Gaule, P., Winrow, D., Mukherjee, N., O’Neill, F., Conlon, N. T., Meiller, J., Collins, D. M., Canonici, A., Fawsi, M. I., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282512 · Cited by 7
Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review
Arslan, M., Asim, M., Sattar, H., Khan, A., Ali, F. T., Zehra, M., & Talluri, K. (2024) · Cureus · doi:10.7759/cureus.70097 · Cited by 8
“The rationale for the approval was derived on the findings of the IMMU-132-01 phase I/II multicenter trial [107].”
MethodUpdate Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
Lux, M. P., Schneeweiß, A., Hartkopf, A. D., Müller, V., Janni, W., Belleville, E., Stickeler, E., Thill, M., Fasching, P. A., Kolberg, H., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1397-7170 · Cited by 7
“In the USA, sacituzumab govitecan has already been authorised on the basis of positive data from the early therapeutic study [40].”
BackgroundUpdate Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
Ditsch, N., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1464-1221 · Cited by 7
“In patients with triple-negative breast cancer, the ADC saci-tuzumab govitecan (SG) represents a new therapy with high efficacy even after some prior therapies [29,30].”
Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier
Witt, J. S., Wisinski, K. B., & Anderson, B. M. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.11.019 · Cited by 7
Recent progress in antibody-based therapeutics for triple-negative breast cancer
Ning, W., Liu, X., Zeng, H.-Y., An, Z., Luo, W., & Xia, N. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2093853 · Cited by 8
“In addition, the receptor tyrosine kinase AXL [126], chondroitin sulfate proteoglycan 4 (CSPG4) [127], the receptor tyrosine kinase EGFR [128,129], intracellular adhesion molecule 1 (ICAM-1) [130], receptor tyrosine kinase-like orphan receptor 1 (ROR1) [131], trophoblast cell surface antigen 2[132], the receptor tyros…”
BackgroundSpira, A. I., Awada, A. H., Isambert, N., Lorente, D., Penel, N., Zhang, Y., Ojalvo, L. S., Hicking, C., Rolfe, A., Ihling, C. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981940 · Cited by 7
Kathpalia, M., Sharma, A., & Kaur, N. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231164110 · Cited by 7
“17 Based on these encouraging findings, SG was considered an impressive drug in patients with mTNBC; however, significant concerns were raised about the drug’s role in causing adverse effects, as this drug has been linked with toxicities such as neutropenia, nausea, anemia, and some others.”
BackgroundAntibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer
Jarroudi, O. A., Bairi, K. E., Curigliano, G., & Afqir, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_1 · Cited by 7
Combination Immunotherapy Strategies in Breast Cancer
Chun, B., Page, D. B., & McArthur, H. L. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00333-3 · Cited by 8
PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs
Dalenc, F., Sarradin, V., Nicolaï, V., Franchet, C., & Ung, M. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.11.007 · Cited by 11
Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
Tu, S., Aydın, A. M., Maraboyina, S., Chen, Z., Singh, S. R. K., Gökden, N., & Langford, T. (2023) · Cancers · doi:10.3390/cancers15092516 · Cited by 7
“It is approved for the treatment of refractory TNBC and metastatic urothelial carcinoma [68,69].”
BackgroundLin, H., Ma, X., Zhu, X., & Zhong, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630056 · Cited by 6
“IMMU-132 is a humanized monoclonal antibody targeting Trop-2, conjugated through a proprietary hydrolyzable linker to SN-38, the active metabolite of the topoisomerase inhibitor irinotecan (57).”
Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
Guo, Q., Lan, T., Lu, Y., Hu, Z., Xu, H., Wang, X., Shao, X., & Fu, X. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.8163 · Cited by 8
“adjuvant treatment against early TNBC [4-7].”
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
Koukoutzeli, C., Trapani, D., Ascione, L., Kotteas, E. A., Marra, A., Criscitiello, C., & Curigliano, G. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241260418 · Cited by 11
Tanegashima, K., Tanaka, Y., Ito, T., Oda, Y., & Nakahara, T. (2024) · Experimental Dermatology · doi:10.1111/exd.15196 · Cited by 6
“…Trophoblast cell-surface antigen 2 (TROP2) is a 36-kDa trans-membrane glycoprotein expressed in the epithelium of various normal tissues, including skin [17, 18], oesophagus and lung, as well as in numerous tumours such as breast, pancreatic, ovarian, prostate, colon and gastric cancers [19–24].”
Marks, J. A., Ahn, J., Reuss, J. E., Barbie, D. A., Altan, M., Gutierrez, M. E., Garassino, M. C., Riely, G. J., Wakelee, H. A., Liu, S. V., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.001 · Cited by 6
Liu, S., Chen, H., Gagea, M., Federico, L., Zhang, F., Gomez, J., Do, K.-A., Symmans, W. F., Hortobágyi, G. N., Mills, G. B., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217775 · Cited by 7
Progress in Gynecologic Cancers with Antibody Drug Conjugates
O’Malley, D. M., & Calo, C. A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01080-4 · Cited by 6
Antibody drug conjugates for patients with breast cancer
Medford, A. J., Spring, L. M., Moy, B., & Bardia, A. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100795 · Cited by 7
Self-citationSeervai, R. N. H., Friske, S. K., Chu, E. Y., Phillips, R. M., Nelson, K. C., Huen, A., Cho, W. C., Aung, P. P., Torres-Cabala, C. A., Prieto, V. G., et al. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14327 · Cited by 6
Li, D., Dai, L., Wang, L., Tan, C., Cai, J., Wang, H., & Zhao, X. (2023) · Applied Organometallic Chemistry · doi:10.1002/aoc.7055 · Cited by 6
Afzal, F., Aiman, W., Zahoor, H., Bajwa, A. R., Kazmi, S. H., Anwar, A., Anwar, M. Y., Rashid, S., Zubair, H., Kashif, T., et al. (2023) · Breast Disease · doi:10.3233/bd-220052 · Cited by 6
“Bardia et al in 2019 [25] studied saci-gov (IMMU-132) in patients with mTNBC who were pretreated with at least two previous therapies for metastatic disease and the drug was well tolerated by most of the patients with significant improvement in median survival rates.”
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
Zhao, J., Xu, W., Zhuo, X., Liu, L., Zhang, J., Jiang, F., Shen, Y., Yan, L., Hou, D., Lin, X., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad115 · Cited by 6
Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
Wright, K., Mittal, A., & Gyawali, B. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000984 · Cited by 6
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
Li, J., & Jiang, Z. (2023) · Cancer · doi:10.1002/cncr.35093 · Cited by 8
Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
Gadaleta‐Caldarola, G., Lanotte, L., Infusino, S., Gadaleta-Caldarola, A., Schipilliti, F. M., Citrigno, C., Petrarota, C., Cusmai, A., & Rizzo, A. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100775 · Cited by 10
Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s
Kozani, P. S., Naseri, A., Kozani, P. S., Khatami, S., & Sheikhi, A. (2021) · Trends in Medical Sciences · doi:10.5812/tms.116686 · Cited by 12
Landmark trials in the medical oncology management of metastatic breast cancer
Lu, P., Santa-Maria, C. A., Ballinger, T. J., & Sheng, J. Y.-S. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.06.003 · Cited by 7
Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study
Li, X., Chen, G., Hu, Y., Zhao, B., & Jiang, J. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001191 · Cited by 7
Breast Cancer Classification Prediction Based on Ultrasonic Image Feature Recognition
Huang, Y., Zheng, S., Lin, Y., & Miao, H. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/4025597 · Cited by 7
RetractedZardavas, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2070064 · Cited by 6
“(n = 108), confirmed the robust activity [27]**.”
BackgroundMakrantonakis, A.-E., Zografos, E., Gazouli, M., Dimitrakakis, K., Toutouzas, K. G., Zografos, C. G., Kalapanida, D., Tsiakou, A., Samelis, G., & Zagouri, F. (2022) · Medicina · doi:10.3390/medicina58101399 · Cited by 8
“For example, the recent FDA approvals of the monoclonal antibody pembrolizumab and the antibody-drug conjugate acituzumab govitecan for the treatment of triple negative breast cancer (TNBC), were considered important milestones in the management of these patients [1,2].”
BackgroundThe triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022
Salimbeni, B. T., Corvaja, C., Valenza, C., Zagami, P., & Curigliano, G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151433 · Cited by 6
“Differently from the anti-Trop2 ADC sacituzumab govitecan (IMMU-132) that has been approved by FDA [26,27], the antiLIV1 ADC ladiratuzumab vedotin (SGN-LIV1A) provided promising results in a phase 1 study that enrolled heavily pretreated TNBC (ORR 32%) [67], but failed to provide a pCR benefit in the neoadjuvant setti…”
BackgroundMethodInfluentialInnovations in targeted therapies for triple negative breast cancer
McCann, K. E., & Hurvitz, S. A. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000671 · Cited by 6
Robinson, A. G. J., KANAAN, Y. M., & Copeland, R. (2020) · Anticancer Research · doi:10.21873/anticanres.14687 · Cited by 6
Orozco, C. T., Edgeworth, M. J., Devine, P. W. A., Hines, A. R., Cornwell, O., Thompson, C. V., Wang, X., Phillips, J. J., Ravn, P., Jackson, S., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00286 · Cited by 6
Yang, H., Bi, Y., Wang, M., Liu, Y., Naseem, A., & Huang, J. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119556 · Cited by 5
Wang, J., Lin, S., Zhang, J., & Su, J. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03876-w · Cited by 6
“Early-phase trials of SG demonstrated promising efficacy, achieving an ORR of 33.3% [18].”
InfluentialPatel, S. P., Gadgeel, S. M., Mino-Kenudson, M. A., Naidoo, J., & Sethakorn, N. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103050 · Cited by 5
Piekarz, J., Picheta, N., Pobideł, J., Szklener, K., & Skórzewska, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679648 · Cited by 5
Nand, P. K., Croucher, D. R., & Khachigian, L. M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218556 · Cited by 5
Laface, C., Giuliani, F., Melaccio, A., Pappagallo, M. N., Santoro, A. N., Perrone, M., Santis, P. D., Guarini, C., Carrozzo, D., & Fedele, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186012 · Cited by 5
“SG initially received breakthrough designation from the US FDA in patients with triple-negative BC who had failed prior therapies for metastatic stage based on the durable RR of 33% by local assessment with a safety profile that was manageable in this patient setting [98].”
MethodExpression Analysis of Early Metastatic Seeding of Colorectal Cancer
Sawada, A., Ohira, M., Hatanaka, K. C., Matsui, H., Ichikawa, N., Yoshida, T., Fukai, M., Matsuno, Y., Homma, S., Hatanaka, Y., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14714-7 · Cited by 6
“47,48 Considering that TROP2 is an independent prognostic factor for OS, its therapeutic application may be expected to improve prognosis.”
Qureshi, Z. A., Jamil, A. R., Fatima, E., Altaf, F., & Siddique, R. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001121 · Cited by 5
“The assessment by Rugo et al (2023), 19 Xu et al (2023), 20 Rugo et al (2022), 22 Bardia et al (2021), 23 Bardia et al (2019), 24 and Bardia et al (2017) 25 utilized the ROB 2 tool.”
Li, Y., Zheng, Y., Liu, T., Zhao, J., Zhou, L., Yang, X., Yao, Z., Wang, X., Fu, Y., Wang, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00466 · Cited by 7
Zhang, Y., Gao, Z., Zhang, Y., Ai, S., Li, W., & Sun, L. (2025) · Biomolecules · doi:10.3390/biom15101375 · Cited by 6
Hormonal and Targeted Treatments in Breast Cancer
Kumar, S., Gupta, S., Maurya, A. P., Rajender, S., & Nigam, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_21 · Cited by 5
Yoshida, K., Noguchi, K., Yamanegi, K., Yoshikawa, K., Kanda, S., Omori, Y., Omae, T., Takaoka, K., Terada, T., Nakano, Y., et al. (2023) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2022.12.008 · Cited by 5
Guerra, E., Trerotola, M., Relli, V., Lattanzio, R., Ceci, M., Boujnah, K., Pantalone, L., Pietro, R. D., Iezzi, M., Tinari, N., et al. (2023) · Cancers · doi:10.3390/cancers15143721 · Cited by 6
“Sacituzumab Govitecan (SG) (TRODELVY, IMMU-132) was approved by the FDA for therapy in patients with metastatic estrogen-receptor positive and triple-negative breast cancer [13,14] and urothelial carcinomas [15].”
BackgroundTrop2: A Key Player in Oncology - From Research to Clinical Application
(2023) · Journal of Genetic Engineering and Biotechnology Research · doi:10.33140/jgebr.05.02.07 · Cited by 5
Chan, B., Lee, J. S., & Yuan, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1305584 · Cited by 6
Zhang, H., Shen, G., Yang, P., Li, J., Li, Z., Liu, Z., Wang, M., Zhao, F., Ren, D., Liu, Z., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104292 · Cited by 5
Tang, Q., Li, H., Zhao, X. T., Li, Z. Y., Xiao, C., Zhou, S. Q., & Chen, D. D. (2024) · World Journal of Oncology · doi:10.14740/wjon1853 · Cited by 5
“All the approaches could possibly report meaningful antitumor activity against targets that are universally expressed in tumors, such is the case of TROP-2-targeted sacituzumab govitecan trial [68, 69].”
BackgroundObozina, A. S., Pakhomov, A. A., Frolova, A. Y., Deyev, S. M., & Shipunova, V. O. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151218 · Cited by 6
Fang, W., Ma, X., & Liu, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2472493 · Cited by 5
“23 We found that seven of the top-10 most co-cited papers (three on HER2-positive breast cancer, 15,24,25 two on HER2-low breast cancer, 16,26 two on TNBC, 27,28 one on solid tumors, 29 and two review articles 30,31 focused on the treat-ment of breast cancer with ADCs (Appendix 7).”
Endocytosis Properties of GD2-Specific Antibodies in Tumor Cells
Makarova, A. O., Titov, M. M., Kalinovsky, D. V., Kholodenko, I. V., Кибардин, А. В., Larin, S. S., Svirshchevskaya, E. V., Deyev, S. M., & Kholodenko, R. V. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297925600395 · Cited by 5
“Among the most promising targets for both therapeutic antibodies and ADCs targeting solid tumor cells are receptors such as HER2 [7], TROP2 [8], nectin-4 [9], FRα [10], TF [11], and EGFR [12].”
Zhao, Y., You, M., Detering, L., Sultan, D. H., Luehmann, H. P., & Liu, Y. (2021) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202000287 · Cited by 5
Loomis, C. P. (2010) · DukeSpace (Duke University) · Cited by 6
Golpich, M., Amini, E., Kefayat, A., Fesharaki, M., & Moshtaghian, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-06368-4 · Cited by 6
Role of sacituzumab govitecan in solid tumors
Veeraballi, S., Khawar, Z., Aslam, H. M., & Muzaffar, M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221092359 · Cited by 5
“that 100% of participants experienced an adverse event of any grade ranging from 1 to 4, 66% of patients experienced an adverse event with a rating of 3, and 19% of patients experienced an adverse event with a rating of 4.(10) The data collected from this study displays that gastrointestinal disorders (nausea, diarrhe…”
BackgroundResultInfluential
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.